^
    almost2years
    Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [C] SHC014748M in healthy Chinese subjects following oral administration. (PubMed, Cancer Chemother Pharmacol)
    SHC014748M was absorbed, metabolized and excreted with unchanged SHC014748M as its main circulating component in plasma following oral administration. In addition, it was speculated that fecal excretion was the principal excretion pathway; meanwhile, monohydroxy, glucuronide conjugation, oxygen, and hydrogenation were the major clearance pathways of SHC014748M through urine and/or feces.
    PK/PD data • Journal
    |
    PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta)
    |
    cybolise (SHC014748M)
    almost4years
    Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma (clinicaltrials.gov)
    P2, N=122, Recruiting, Nanjing Sanhome Pharmaceutical, Co., Ltd. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    cybolise (SHC014748M)
    4years
    SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia. (PubMed, Neoplasia)
    CCL4, CCL17, CCL22 and CXCL13 in patient serum decreased sharply after SHC014748M treatment. According to the results, SHC014748M appeared to be a novel promising compound in the treatment of B cell lymphomas and CLL.
    Preclinical • Journal
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13) • CCL4 (Chemokine (C-C motif) ligand 4) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL22 (C-C Motif Chemokine Ligand 22) • CCL7 (Chemokine (C-C motif) ligand 7)
    |
    cybolise (SHC014748M)